Personalizing Cardiac Medicine

	Tweet

Improving patient care by “personalizing” the practice of medicine often results from studying specific drugs and their impact of genetic biomarkers.

New research underway at GW by Travis O’Brien, PhD, looks at the drug warfarin, an oral anticoagulant used to treat individuals with certain cardiovascular diseases warfarin accounts for several million prescriptions each year. With its narrow therapeutic index, warfarin may not be well tolerated by certain individuals because of their genetic makeup, says Dr. O’Brien, associate professor of Pharmacology and Physiology

O’Brien and a team of researchers hope to unlock the key to the personalization of warfarin therapy based on a patient’s genetic biomarkers. The multidisciplinary research team also includes April Barbour, MD, assistant professor of Medicine, Linda Lesky, MD, associate professor of Medicine and Health Policy, and Perry Payne Jr., MD, JD, MPP, assistant research professor of Health Policy. 

In addition, the study will be conducted in collaboration with GW adjunct faculty, Arthur Harralson, PharmD, and Robert Kidd, PharmD, PhD, from Shenandoah University, Bernard J. Dunn School of Pharmacy.

As part of the study, samples will be collected at the Medical Faculty Associates. DNA from the samples will then be isolated and analyzed at the GW Pharmacogenomics Program laboratory, located at GW’s Ashburn, Va., campus. The analyzed samples will then be subject to DNA sequencing, which is undertaking in the Department of Pharmacology and Physiology’s Core Sequencing Facility located in Ross Hall.

“We believe that research aimed at decreasing the health care costs associated with stabilizing patients’ wafarin dosing potentially can work as a preventative measure to decrease the incidence of adverse drug reactions associated warfarin,” Dr. O’Brien said.

Source: George Washington University

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]